Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sigma-Tau Research, Inc.
The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Stage 0-III breast cancer in which adjuvant radiation is indicated;
Qualifying Brief Fatigue Inventory (BFI) score 6. -
You may not be if
Medication to treat or manage fatigue and pain
Use of erythropoietin to control anemia
Clinical evidence of hypothyroidism or hyperthyroidism
Clareo Health | Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue
